In this study, genomic profiles revealed that MET copy number gain was unique to non-responders, and this suggests that consolidating co-inhibition of PD-1 with MET could enhance the clinical benefit of immunotherapies in HCC patients. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.